Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 16

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 16
---
.

After giving effect to the sale by us of common shares
in the aggregate amount of $4,006,544 at an assumed offering price of $2.53 per share, the last reported sale price of our common shares
on Nasdaq on September 5, 2025, and after deducting commissions and estimated offering expenses, our as adjusted net tangible book value
as of June 30, 2025 would have been approximately $15.7 million, or $1.83 per share. This represents an immediate increase in net tangible
book value of $0.10 per share to existing shareholders and an immediate dilution of $0.70 per share to new investors purchasing common
shares in this offering. The following table illustrates this dilution:

| Assumed offering price per common share                                                                       |         | $  2.53 |
| Net tangible book value per common share as of June 30, 2025                                                  | $  1.73 |         |
| Increase in as adjusted net tangible book value per common share attributable to the offering                 | $  0.10 |         |
| As adjusted net tangible book value per common share as of June 30, 2025 after giving effect to this offering |         | $  1.83 |
| Dilution per common share to new investors participating in this offering                                     |         | $  0.70 |

The table above assumes for illustrative purposes that
an aggregate of 1,583,614 common shares are sold during the term of the Sales Agreement with the Sales Agent at a price of $2.53 per share,
the last reported sale price of our common shares on Nasdaq on September 5, 2025, for aggregate gross proceeds of $4,006,544. The common
shares subject to the Sales Agreement are being sold from time to time at various prices. This information is supplied for illustrative
purposes only and may differ based on the actual offering price and the actual number of shares offered.

The number of our common shares to be outstanding after the offering is based on 7,022,678 of our
common shares outstanding as of June 30, 2025 and excludes:

| · | 378,235 of our common shares issuable upon exercise of outstanding options granted under our equity incentive plans at a weighted 
 average exercise price of $24.71 per share;                                                                                       |

| · | 117,967 of our common shares issuable upon conversion of